227.59
+0.06%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arvee Laboratories (India)
Its shares trade on NSE under the ticker ARVEE.NS. It has been listed since 22 February 2018. In the fiscal year to 31 March 2026, it reported revenue of ₹315.1m and net income of ₹25.3m. At that date it held total assets of ₹432.6m and shareholders' equity of ₹337.9m.
Arvee Laboratories (India) Ltd. provides chemical products, which includes polymer modifiers, contrast media and drug intermediates. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2018-02-22. The firm's product categories include polymer modifiers, contrast media intermediates and drug intermediates. Its polymer modifiers products include Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt and 5-Sodiosulfo-Bis-(B-Hydroxyethyl)-Isophthalate. The firm's contrast media intermediates products include 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. Its drug intermediates products include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine and 2-Chloro-5-Nitrobenzoic Acid.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 22 Feb 2018
- Employees
- 67
- Website
- arveelabs.com ↗
Leadership
Pay as last reported
- Mr. Maulesh RavalChief Financial Officer
- Ms. Neelam ChotraniCompany Secretary & Compliance Officer
- Shri. Shalin PatelManaging Director, Director, since 2014
- Mr. Saurin GandhiAdditional Director
- Mr. Praveen MishraAdditional Director
- Mr. Saumil ChokshiNon-Executive Director
- Ms. Chandrakala BhattAdditional Non-Executive Independent Director
- Mr. Vishal MehtaAdditional Non-Executive Independent Director
- Mr. Amishkumar ShahAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arvee Laboratories offers polymer modifiers like Dimethyl 5-Sodiosulfoisophthalate to the chemical market.
- The firm provides contrast media intermediates such as 5-Nitroisophthalic acid for industrial use.
- Drug intermediates include 2-Acetyl Thiophene and Thiophene-2-Carboxaldehyde for pharmaceutical applications.
Weaknesses
- The company employs only 67 full-time staff members in Ahmedabad.
- Arvee Laboratories is a small entity listed on February 22, 2018.
- The business operates solely within the Indian market from Gujarat.
Opportunities
- Expanding the range of polymer modifiers could attract more industrial clients.
- Growing demand for contrast media intermediates offers potential revenue growth.
- Increasing need for drug intermediates like 4-Amino Pyridine supports market expansion.
Threats
- Competition in the chemical sector may pressure profit margins significantly.
- Economic fluctuations in India could impact the demand for materials.
- Supply chain disruptions might affect the production of specific intermediates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.